Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective.

Intravenously injected nanoparticulate drug carriers provide a wide range of unique opportunities for site-specific targeting of therapeutic agents to many areas within the vasculature and beyond. Pharmacokinetics and biodistribution of these carriers are controlled by a complex array of interrelated core and interfacial physicochemical and biological factors. Pertinent to realizing therapeutic goals, definitive maps that establish the interdependency of nanoparticle size, shape, and surface characteristics in relation to interfacial forces, biodistribution, controlled drug release, excretion, and adverse effects must be outlined. These concepts are critically evaluated and an integrated perspective is provided on the basis of the recent application of nanoscience approaches to nanocarrier design and engineering. The future of this exciting field is bright; some regulatory-approved products are already on the market and many are in late-phase clinical trials. With concomitant advances in extensive computational knowledge of the genomics and epigenomics of interindividual variations in drug responses, the boundaries toward development of personalized nanomedicines can be pushed further.

[1]  M Ferrari,et al.  The effect of shape on the margination dynamics of non-neutrally buoyant particles in two-dimensional shear flows. , 2008, Journal of biomechanics.

[2]  C. Jaffe,et al.  Reduction of myocardial ischemia during percutaneous transluminal coronary angioplasty with oxygenated Fluosol. , 1990, The American journal of cardiology.

[3]  S. Moein Moghimi,et al.  Recognition by Macrophages and Liver Cells of Opsonized Phospholipid Vesicles and Phospholipid Headgroups , 2004, Pharmaceutical Research.

[4]  Xu Wang,et al.  Application of Nanotechnology in Cancer Therapy and Imaging , 2008, CA: a cancer journal for clinicians.

[5]  Theresa M Allen,et al.  Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. , 2004, Biochimica et biophysica acta.

[6]  M. Bawendi,et al.  Renal clearance of quantum dots , 2007, Nature Biotechnology.

[7]  Herbert J Meiselman,et al.  Antibody against poly(ethylene glycol) adversely affects PEG‐asparaginase therapy in acute lymphoblastic leukemia patients , 2007, Cancer.

[8]  Mark E. Davis,et al.  Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.

[9]  Kenneth A. Dawson,et al.  Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts , 2008, Proceedings of the National Academy of Sciences.

[10]  T. Andresen,et al.  Mechanistic study of the sPLA2-mediated hydrolysis of a thio-ester pro anticancer ether lipid. , 2009, Journal of the American Chemical Society.

[11]  S. Davis,et al.  Non-phagocytic uptake of intravenously injected microspheres in rat spleen: influence of particle size and hydrophilic coating. , 1991, Biochemical and biophysical research communications.

[12]  S. Moghimi,et al.  Endothelial cells as therapeutic targets in cancer: new biology and novel delivery systems. , 2003, Critical reviews in therapeutic drug carrier systems.

[13]  P. Cullis,et al.  Drug Delivery Systems: Entering the Mainstream , 2004, Science.

[14]  E Froehlich,et al.  Dendrimers bind human serum albumin. , 2009, The journal of physical chemistry. B.

[15]  P. Cullis,et al.  β2-Glycoprotein I Is a Major Protein Associated with Very Rapidly Cleared Liposomes in Vivo, Suggesting a Significant Role in the Immune Clearance of "Non-self" Particles (*) , 1995, The Journal of Biological Chemistry.

[16]  I. Venditti,et al.  Lipolytic enzymes with improved activity and selectivity upon adsorption on polymeric nanoparticles. , 2007, Biomacromolecules.

[17]  T. Allen Ligand-targeted therapeutics in anticancer therapy , 2002, Nature Reviews Cancer.

[18]  S. Takeoka,et al.  Selective uptake of surface-modified phospholipid vesicles by bone marrow macrophages in vivo. , 2007, Biomaterials.

[19]  D. Ahmadvand,et al.  Biological targeting and innovative therapeutic interventions with phage-displayed peptides and structured nucleic acids (aptamers). , 2011, Current opinion in biotechnology.

[20]  Daniel Irimia,et al.  Synthetic microvascular networks for quantitative analysis of particle adhesion , 2008, Biomedical microdevices.

[21]  M Ferrari,et al.  The adhesive strength of non-spherical particles mediated by specific interactions. , 2006, Biomaterials.

[22]  O. Bourdon,et al.  Relationship between complement activation, cellular uptake and surface physicochemical aspects of novel PEG-modified nanocapsules. , 2001, Biomaterials.

[23]  Taro Shimizu,et al.  PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[24]  R. Mahley,et al.  Chylomicron metabolism. Chylomicron uptake by bone marrow in different animal species. , 1989, The Journal of biological chemistry.

[25]  S. Moghimi,et al.  Critical issues in site-specific targeting of solid tumours: the carrier, the tumour barriers and the bioavailable drug , 2008, Expert opinion on drug delivery.

[26]  S. Moghimi,et al.  Liposome-Mediated Triggering of Complement Cascade , 2008, Journal of liposome research.

[27]  Ji-Ho Park,et al.  Differential proteomics analysis of the surface heterogeneity of dextran iron oxide nanoparticles and the implications for their in vivo clearance. , 2009, Biomaterials.

[28]  T. Gray,et al.  A single dose of intravenously injected poloxamine-coated long-circulating particles triggers macrophage clearance of subsequent doses in rats. , 1997, Clinical science.

[29]  Sara Linse,et al.  Detailed identification of plasma proteins adsorbed on copolymer nanoparticles. , 2007, Angewandte Chemie.

[30]  Janos Szebeni,et al.  Methylation of the phosphate oxygen moiety of phospholipid‐methoxy(polyethylene glycol) conjugate prevents PEGylated liposome‐mediated complement activation and anaphylatoxin production , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  Robin Fåhræus,et al.  THE VISCOSITY OF THE BLOOD IN NARROW CAPILLARY TUBES , 1931 .

[32]  Samir Mitragotri,et al.  Designer Biomaterials for Nanomedicine , 2009 .

[33]  C. Lemere,et al.  Novel Therapeutic Approach for the Treatment of Alzheimer's Disease by Peripheral Administration of Agents with an Affinity to β-Amyloid , 2003, The Journal of Neuroscience.

[34]  Patrick Couvreur,et al.  Translocation of poly(ethylene glycol-co-hexadecyl)cyanoacrylate nanoparticles into rat brain endothelial cells: role of apolipoproteins in receptor-mediated endocytosis. , 2007, Biomacromolecules.

[35]  D. Hochstrasser,et al.  Colloidal carriers for intravenous drug targeting: Plasma protein adsorption patterns on surface‐modified latex particles evaluated by two‐dimensional polyacrylamide gel electrophoresis , 1993, Electrophoresis.

[36]  S. Moghimi,et al.  Causative factors behind poloxamer 188 (Pluronic F68, Flocor)-induced complement activation in human sera. A protective role against poloxamer-mediated complement activation by elevated serum lipoprotein levels. , 2004, Biochimica et biophysica acta.

[37]  Barbara Klajnert,et al.  Haemolytic activity of polyamidoamine dendrimers and the protective role of human serum albumin , 2010, Proceedings of the Royal Society A: Mathematical, Physical and Engineering Sciences.

[38]  H. Dai,et al.  In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. , 2020, Nature nanotechnology.

[39]  Joseph M. DeSimone,et al.  Strategies in the design of nanoparticles for therapeutic applications , 2010, Nature Reviews Drug Discovery.

[40]  D. Peng,et al.  HDL and immunomodulation: an emerging role of HDL against atherosclerosis , 2010, Immunology and cell biology.

[41]  Robert Langer,et al.  On firm ground: IP protection of therapeutic nanoparticles , 2010, Nature Biotechnology.

[42]  S M Moghimi,et al.  Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.

[43]  Maurizio Prato,et al.  Carbon-nanotube shape and individualization critical for renal excretion. , 2008, Small.

[44]  A. C. Hunter,et al.  Nanomedicine: current status and future prospects , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[45]  Weibo Cai,et al.  Circulation and long-term fate of functionalized, biocompatible single-walled carbon nanotubes in mice probed by Raman spectroscopy , 2008, Proceedings of the National Academy of Sciences.

[46]  Mauro Ferrari,et al.  Design of bio-mimetic particles with enhanced vascular interaction. , 2009, Journal of biomechanics.

[47]  Thomas Vorup-Jensen,et al.  Curvature of Synthetic and Natural Surfaces Is an Important Target Feature in Classical Pathway Complement Activation , 2010, The Journal of Immunology.

[48]  Robert Langer,et al.  Immunocompatibility properties of lipid-polymer hybrid nanoparticles with heterogeneous surface functional groups. , 2009, Biomaterials.

[49]  Thomas L Andresen,et al.  Enzyme-triggered nanomedicine: Drug release strategies in cancer therapy (Invited Review) , 2010, Molecular membrane biology.

[50]  B. Nilsson,et al.  Conformational epitopes of C3 reflecting its mode of binding to an artificial polymer surface. , 1993, Molecular immunology.

[51]  D. Simberg,et al.  Interactions of nanoparticles with plasma proteins: implication on clearance and toxicity of drug delivery systems , 2011, Expert opinion on drug delivery.

[52]  Doriano Brogioli,et al.  Lipid-based nanoparticles with high binding affinity for amyloid-beta1-42 peptide. , 2010, Biomaterials.

[53]  Mauro Ferrari,et al.  Intravascular Delivery of Particulate Systems: Does Geometry Really Matter? , 2008, Pharmaceutical Research.

[54]  Samir Mitragotri,et al.  Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[55]  Jun Fang,et al.  The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. , 2011, Advanced drug delivery reviews.

[56]  S Moein Moghimi,et al.  Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere-serum interface: implications for stealth nanoparticle engineering. , 2010, ACS nano.

[57]  P. Cullis,et al.  Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. , 1992, The Journal of biological chemistry.

[58]  J. Brash,et al.  Protein adsorption to polyethylene glycol modified liposomes from fibrinogen solution and from plasma. , 2001, Biochimica et biophysica acta.

[59]  Bo Nilsson,et al.  C3 Adsorbed to a Polymer Surface Can Form an Initiating Alternative Pathway Convertase1 , 2002, The Journal of Immunology.

[60]  D. Discher,et al.  Shape effects of filaments versus spherical particles in flow and drug delivery. , 2007, Nature nanotechnology.

[61]  A. Popel,et al.  A two-phase model for flow of blood in narrow tubes with increased effective viscosity near the wall. , 2001, Biorheology.

[62]  H. Dai,et al.  Complement activation by PEGylated single-walled carbon nanotubes is independent of C1q and alternative pathway turnover. , 2008, Molecular immunology.

[63]  R. Jain,et al.  Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[64]  Magnus Bergkvist,et al.  Paradoxical glomerular filtration of carbon nanotubes , 2010, Proceedings of the National Academy of Sciences.

[65]  L. Munn,et al.  Aberrant vascular architecture in tumors and its importance in drug-based therapies. , 2003, Drug discovery today.

[66]  D. Devine,et al.  The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. , 1991, Journal of immunology.

[67]  M Ferrari,et al.  The receptor-mediated endocytosis of nonspherical particles. , 2008, Biophysical journal.

[68]  H. Goldsmith,et al.  Margination of leukocytes in blood flow through small tubes. , 1984, Microvascular research.

[69]  D. Tzemach,et al.  Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma , 2000, Cancer.

[70]  T. Andresen,et al.  Activation of the Human Complement System by Cholesterol-Rich and PEGylated Liposomes—Modulation of Cholesterol-Rich Liposome-Mediated Complement Activation by Elevated Serum LDL and HDL Levels , 2006, Journal of liposome research.

[71]  P. Couvreur,et al.  Analysis of plasma protein adsorption onto PEGylated nanoparticles by complementary methods: 2‐DE, CE and Protein Lab‐on‐chip® system , 2007, Electrophoresis.

[72]  J Szebeni,et al.  Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. , 2003, Progress in lipid research.

[73]  Stephanie E. A. Gratton,et al.  The effect of particle design on cellular internalization pathways , 2008, Proceedings of the National Academy of Sciences.

[74]  Poloxamer-188 revisited: a potentially valuable immune modulator. , 1996, Journal of the National Cancer Institute.

[75]  S. Radford,et al.  Nucleation of protein fibrillation by nanoparticles , 2007, Proceedings of the National Academy of Sciences.

[76]  J. Weinstein,et al.  Interaction of unilamellar liposomes with serum lipoproteins and apolipoproteins. , 1980, Journal of lipid research.

[77]  G. Vercellotti,et al.  Activation of plasma complement by perfluorocarbon artificial blood: probable mechanism of adverse pulmonary reactions in treated patients and rationale for corticosteroids prophylaxis , 1982 .

[78]  J Szebeni,et al.  Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: the challenges ahead. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[79]  S. Chow,et al.  Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer , 2003, Anti-cancer drugs.

[80]  Samir Mitragotri,et al.  Physical approaches to biomaterial design. , 2009, Nature materials.

[81]  Dipak K. Sarker,et al.  Concentration dependent structural ordering of poloxamine 908 on polystyrene nanoparticles and their modulatory role on complement consumption. , 2006, Journal of nanoscience and nanotechnology.

[82]  Ya‐Ping Sun,et al.  Covalently PEGylated carbon nanotubes with stealth character in vivo. , 2008, Small.

[83]  Piet Gros,et al.  Structure of C3b reveals conformational changes that underlie complement activity , 2006, Nature.

[84]  T. Ishida,et al.  Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[85]  S. Perkins,et al.  Solution structure of human and mouse immunoglobulin M by synchrotron X-ray scattering and molecular graphics modelling. A possible mechanism for complement activation. , 1991, Journal of molecular biology.

[86]  Iseult Lynch,et al.  Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. , 2011, Journal of the American Chemical Society.

[87]  S. Moghimi Mechanisms of splenic clearance of blood cells and particles : towards development of new splenotropic agents , 1995 .

[88]  M. Ferrari,et al.  A Theoretical Model for the Margination of Particles within Blood Vessels , 2005, Annals of Biomedical Engineering.

[89]  Malcolm L. H. Green,et al.  Complement activation and protein adsorption by carbon nanotubes. , 2006, Molecular immunology.

[90]  Kapil Pant,et al.  A physiologically realistic in vitro model of microvascular networks , 2009, Biomedical microdevices.

[91]  Moghimi,et al.  Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system - The concept of tissue specificity. , 1998, Advanced drug delivery reviews.

[92]  M. Ferrari Cancer nanotechnology: opportunities and challenges , 2005, Nature Reviews Cancer.

[93]  M. Gobbi,et al.  Curcumin-decorated nanoliposomes with very high affinity for amyloid-β1-42 peptide. , 2011, Biomaterials.

[94]  K. Sou,et al.  Bone marrow-targeted liposomal carriers , 2011, Expert opinion on drug delivery.

[95]  M Ferrari,et al.  Size and shape effects in the biodistribution of intravascularly injected particles. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[96]  S. Moghimi,et al.  Capture of stealth nanoparticles by the body's defences. , 2001, Critical reviews in therapeutic drug carrier systems.

[97]  P. Cossart Host/pathogen interactions. Subversion of the mammalian cell cytoskeleton by invasive bacteria. , 1997, The Journal of clinical investigation.

[98]  L. Harker Platelets and vascular thrombosis. , 1994, The New England journal of medicine.

[99]  J. Karp,et al.  Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .

[100]  Betty Y. S. Kim,et al.  Current concepts: Nanomedicine , 2010 .

[101]  Jing Zhao,et al.  Interaction between apolipoproteins A-I and A-II and the membrane attack complex of complement. Affinity of the apoproteins for polymeric C9. , 1993, The Journal of biological chemistry.

[102]  D. Hourcade,et al.  Properdin Can Initiate Complement Activation by Binding Specific Target Surfaces and Providing a Platform for De Novo Convertase Assembly1 , 2007, The Journal of Immunology.

[103]  Arezou A Ghazani,et al.  Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. , 2006, Nano letters.

[104]  Mauro Ferrari,et al.  Design maps for nanoparticles targeting the diseased microvasculature. , 2008, Biomaterials.

[105]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[106]  James H. Adair,et al.  Nanoparticulate alternatives for drug delivery. , 2010, ACS nano.

[107]  S. Moghimi,et al.  Complement monitoring of carbon nanotubes. , 2010, Nature nanotechnology.

[108]  J. C. Roberts,et al.  Preliminary biological evaluation of polyamidoamine (PAMAM) Starburst dendrimers. , 1996, Journal of biomedical materials research.

[109]  Samir Mitragotri,et al.  Flow and adhesion of drug carriers in blood vessels depend on their shape: a study using model synthetic microvascular networks. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[110]  T. Andresen,et al.  Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. , 2005, Progress in lipid research.

[111]  S. Gordon,et al.  Monocyte and macrophage heterogeneity , 2005, Nature Reviews Immunology.

[112]  A. Weintraub,et al.  Mannan-binding lectin activates C3 and the alternative complement pathway without involvement of C2 , 2006 .

[113]  D. Peer,et al.  Systemic Leukocyte-Directed siRNA Delivery Revealing Cyclin D1 as an Anti-Inflammatory Target , 2008, Science.

[114]  Kenneth A. Dawson,et al.  Protein–Nanoparticle Interactions , 2008, Nano-Enabled Medical Applications.

[115]  S. Davis,et al.  Enhanced hepatic clearance of intravenously administered sterically stabilized microspheres in zymosan‐stimulated rats , 1993, Journal of leukocyte biology.

[116]  S Gordon,et al.  Macrophage receptors and immune recognition. , 2005, Annual review of immunology.

[117]  R. Gurny,et al.  An investigation on the role of plasma and serum opsonins on the internalization of biodegradable poly(D,L-lactic acid) nanoparticles by human monocytes. , 1995, Life sciences.